Compare AbbVie Inc (ABBV) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Open Text Corporation — how do they compare? AbbVie Inc trades at $253.75 (market cap $449.91B), while Open Text Corporation trades at $22.62 (market cap $5.65B). The key difference: AbbVie Inc is far larger — about 79.6× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| ABBV | OTEX | |
|---|---|---|
Market Cap | $449.91B | $5.65B |
Sector | Health | Technology |
52-Week High | $261.07 | $39.69 |
52-Week Low | $184.85 | $20.01 |
Enterprise Value | $513.38B | $10.81B |
Dividend Yield | 2.72% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
OTEX trades at $22.57, down 2.04% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.95 and net income margin of 9.91%, supported by recent earnings beats. Recent news highlights strategic investments in AI and sovereign cloud in Europe, alongside a dividend payment scheduled for June 19, 2026.
The outlook is mixed; analyst consensus targets $29.75 (31.8% upside) with 42% buy ratings, but technical indicators suggest near-term pressure. Risks include execution of growth initiatives and market volatility. The stock presents a value opportunity if AI investments drive future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
